GenapSys and Twist Partner to Bring Next-Generation Sequencing Target Enrichment and Library Preparation to Most Accessible Highly Accurate Sequencer

REDWOOD CITY, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–GenapSys Inc., the company behind the world’s first highly accurate, affordable, and portable gene sequencer, today announced a new OEM partnership with Twist Bioscience, a company enabling customers to succeed through its offering of high-quality synthetic DNA. The collaboration will bring a broad and comprehensive range of target enrichment and library preparation tools for next-generation sequencing (NGS) to the GenapSys high accuracy Sequencer offering. Twist’s products will further empower owners of GenapSys’s next-generation sequencer to conduct research in oncology, whole-exome sequencing, rare diseases, viral outbreaks, drug discovery, and more in a simple solution.


The partnership provides significant benefit to customers who will now have the ability to work with a single vendor, cutting down on paperwork and eliminating costly time delays through the convenience of “one stop” shopping. Additionally, research laboratories will have the peace of mind of knowing that the enrichment tools and the gene sequencer will work harmoniously together.

“This OEM collaboration with GenapSys provides an ideal option for research laboratories, government organizations and sequencing providers, including healthcare facilities, to get access to our assays on GenapSys distributed sequencers,” explained Emily M. Leproust, Ph.D., CEO and Co-Founder of Twist Bioscience. “We believe in bringing best-in-class solutions together to offer customers optimal workflows for their needs, and with the distributed nature of the GenapSys high accuracy and affordable sequencer, there is the potential for wider adoption, benefitting a greater number of researchers and clinicians.”

“We’re thrilled to work with an industry leader like Twist Bioscience to give our customers the flexibility and comprehensive capabilities they need from target-enriched, high-quality libraries on our high accuracy sequencing solution, in a single offering,” said Dr. Hesaam Esfandyarpour, Founder and CEO of GenapSys. “Through this partnership, GenapSys enables researchers to have access to an efficient, end-to-end sequencing solution with almost limitless applications in life sciences.”

The collaboration with Twist Bioscience will take effect immediately, with GenapSys integrating the new library preparation and target enrichment products starting in Q2 2020. With the addition of the Twist Bioscience solutions, Genapsys customers will gain access to advanced genomic tools. Researchers will be able to leverage the powerful combination of Twist Bioscience and GenapSys for:

  • Tracking of viral outbreaks such as the novel Coronavirus test
  • Exome Sequencing for identification of inherited diseases
  • Developing tests for cancer detection and monitoring
  • Drug discovery and development
  • Finding therapies for rare diseases

GenapSys and Twist Bioscience will be attending the Advances in Genome Biology and Technology (AGBT) General Meeting from February 23-26 in Marco Island, Florida. GenapSys will be hosting several presentations from leading genomics researchers as they share their findings and experiences using the GenapSys platform and the outstanding performance data on several applications, including the gold standard accuracy in SNV detection. Presentation topics include; the sequencing of microbes from extreme environments, detection of biologically important – repetitive RNA elements, calling of single nucleotide variants at lower coverage amounts vs comparable technologies, whole exome sequencing, high sensitivity somatic mutation detections in cancer panels, and more.

Interested conference attendees can visit GenapSys at their suite in room Osprey 7, and Twist Bioscience in Caxambus 1, throughout the week, including the four GenapSys’s presentations on Monday and Tuesday, 8:30am, 10:30am in Osprey 7, and posters #209 and #418.

Researchers and clinicians interested in more information on the integration of the Twist Bioscience tools, or parties interested in partnering with GenapSys can contact the company directly via

About GenapSys Inc.

GenapSys is the company behind the world’s first highly accurate direct electronic sequencing technology. Its system leverages a proprietary electrical microfluidic sequencing chip with a scalable number of detectors, allowing for applications ranging from targeted sequencing of specific amplicons to genome-scale sequencing data collection. The proprietary semiconductor chip-based detection modality allows the system to be compact, scalable, and affordable, empowering the democratization of access to Next-Generation Sequencing, and bringing the power of high-quality genomics into the hands of every researcher or clinician.

Founded by Dr. Hesaam Esfandyarpour, GenapSys’ novel sequencing method is revolutionizing genomics discovery, biomedical research, healthcare, diagnostics, agriculture, and a variety of other fields. GenapSys is headquartered in Redwood City, CA. For more information, visit

Follow us on Twitter | | LinkedIn

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Check Also

Pfizer and EMD Serono Terminate Phase 3 Study of Avelumab Plus CRT for Treatment of Head and Neck Cancer

ROCKLAND, Mass. and NEW YORK, March 13, 2020 /PRNewswire/ — EMD Serono, the biopharmaceutical business …